In The Digital Therapeutics Explainer, Business Insider Intelligence will explore the drivers lighting a fire under the DTx market, identify the leading DTx market players, and unpack the varied ways vendors reach their intended audiences. We will also assess both the opportunities and risks DTx companies and their products pose to payers, pharmaceutical companies, and medtech firms. Finally, we will forecast what we expect to see next in the DTx space and outline the barriers holding DTx firms back to help stakeholders navigate the crowding field and develop strategies to capture a piece of the DTx pie.
The companies mentioned in this report include: 23andMe, Apple, Bayer, Blue Shield of California, CVS Caremark, Eli Lilly, Noom, Novartis, Novo Nordisk, ResMed, Roche, Sanofi, UnitedHealth Group, Walgreens, and Walmart, among others.
In full, this exclusive report:
Provides a roadmap to the digital therapeutics market and explains how companies developing digital drug alternatives are transforming healthcare Identifies key players operating in the space Explores how digital therapeutics stand to benefit — and threaten — entrenched players, like payers, pharmaceutical companies, and medical device makers Considers what the future of digital therapeutics looks like and what still stands in the way of their proliferation
Interested in more digital health research? Buy our Ultimate Digital Health Reports Bundle and get all the reports you'll need to stay ahead of emerging trends in the industry. You'll get immediate access to this report and 15 others on some of the most important topics impacting the healthcare industry. |
|
